Furthermore, locoregional therapy modifies the tumor microenvironment, for instance, by promoting the release of VEGF and hypoxia-inducible factor-1α (HIF-1α), which further potentiates the effect of targeted agents. The gene discussed is HIF1A; the disease is neoplasm.